Identification of risk factors associated with oral 5-aminolevulinic acid-induced hypotension in photodynamic diagnosis for non-muscle invasive bladder cancer: a multicenter retrospective study

[1]  T. Karashima,et al.  Identification of risk factors for post-induction hypotension in patients receiving 5-aminolevulinic acid: a single-center retrospective study , 2020, JA Clinical Reports.

[2]  Shahrokh F. Shariat,et al.  European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. , 2019, European urology.

[3]  H. Yaegashi,et al.  Intraoperative hypotension caused by oral administration of 5‐aminolevulinic acid for photodynamic diagnosis in patients with bladder cancer , 2019, International journal of urology : official journal of the Japanese Urological Association.

[4]  T. Yatabe,et al.  5-Aminolevulinic acid-induced severe hypotension during transurethral resection of a bladder tumor: a case report , 2019, JA Clinical Reports.

[5]  A. Slooter,et al.  Intraoperative hypotension and the risk of postoperative adverse outcomes: a systematic review , 2018, British journal of anaesthesia.

[6]  T. Tsuzuki,et al.  Oral 5‐aminolevulinic acid‐mediated photodynamic diagnosis using fluorescence cystoscopy for non‐muscle‐invasive bladder cancer: A multicenter phase III study , 2018, International journal of urology : official journal of the Japanese Urological Association.

[7]  Publisher's Note , 2018, Anaesthesia.

[8]  W. Stummer,et al.  Randomized, Prospective Double-Blinded Study Comparing 3 Different Doses of 5-Aminolevulinic Acid for Fluorescence-Guided Resections of Malignant Gliomas , 2017, Neurosurgery.

[9]  S. Eljamel,et al.  Risk factors for developing oral 5-aminolevulinic acid-induced side effects in patients undergoing fluorescence guided resection. , 2013, Photodiagnosis and photodynamic therapy.

[10]  Dieter Jocham,et al.  Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. , 2013, European urology.

[11]  Herbert Stepp,et al.  Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. , 2013, European urology.

[12]  O. Aboumarzouk,et al.  Oral 5-aminolevulinic acid induced Photodynamic Diagnostic Ureterorenoscopy--does the blood pressure require monitoring? , 2013, Photodiagnosis and photodynamic therapy.

[13]  Bernhard Walter,et al.  Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. , 2007, Urology.

[14]  Herbert Stepp,et al.  Seven years' experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. , 2007, Urology.

[15]  N. Abraham,et al.  Protoporphyrin IX Generation from ä‐Aminolevulinic Acid Elicits Pulmonary Artery Relaxation and Soluble Guanylate Cyclase Activation , 2006, American journal of physiology. Lung cellular and molecular physiology.

[16]  Herbert Stepp,et al.  Role of 5‐aminolevulinic acid in the detection of urothelial premalignant lesions , 2002, Cancer.

[17]  A. Straughn,et al.  Clinical pharmacokinetics of 5-aminolevulinic acid in healthy volunteers and patients at high risk for recurrent bladder cancer. , 2002, The Journal of pharmacology and experimental therapeutics.

[18]  T. Stephenson,et al.  Photodynamic therapy for dysplastic Barrett's oesophagus: a prospective, double blind, randomised, placebo controlled trial , 2000, Gut.

[19]  P. Siersema,et al.  Porphyrin biosynthesis in human Barrett's oesophagus and adenocarcinoma after ingestion of 5-aminolaevulinic acid , 2000, British Journal of Cancer.

[20]  U. Wetterauer,et al.  Intravesical administration of 5-aminolevulinic acid (5-ALA) Safety and pharmacokinetics of 5-ALA and its metabolite protoporphyrin IX , 2000, European Journal of Clinical Pharmacology.

[21]  A B Houtsmuller,et al.  5-Aminolaevulinic acid-induced protoporphyrin IX accumulation in tissues: pharmacokinetics after oral or intravenous administration. , 1998, Journal of photochemistry and photobiology. B, Biology.

[22]  D. Kessel,et al.  Plasma levels of protoporphyrin IX in humans after oral administration of 5-aminolevulinic acid. , 1997, Journal of photochemistry and photobiology. B, Biology.